Rational Design of Palladium(II) Indenyl and Allyl Complexes Bearing Phosphine and Isocyanide Ancillary Ligands with Promising Antitumor Activity
Molecules · 2024
DOI: 10.3390/molecules29020345 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Enrica Bortolamiol und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Sciences and Nanosystems, Università Ca' Foscari, Campus Scientifico, Via Torino 155, 30174 Venezia, Italy. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Breast Neoplasms, Phosphines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Fondazione AIRC per la Ricerca sul Cancro.
Abstract (Originalsprache)
A new class of palladium–indenyl complexes characterized by the presence of one bulky alkyl isocyanide and one aryl phosphine serving as ancillary ligands has been prepared, presenting high yields and selectivity. All the new products were completely characterized using spectroscopic and spectrometric techniques (NMR, FT-IR, and HRMS), and, for most of them, it was also possible to define their solid-state structures via X-ray diffractometry, revealing that the indenyl fragment always binds to the metal centre with a hapticity intermediate between ƞ3 and ƞ5. A reactivity study carried out using piperidine as a nucleophilic agent proved that the indenyl moiety is the eligible site of attack rather than the isocyanide ligand or the metal centre. All complexes were tested as potential anticancer agents against three ovarian cancer cell lines (A2780, A2780cis, and OVCAR-5) and one breast cancer cell line (MDA-MB-231), displaying comparable activity with respect to cisplatin, which was used as a positive control. Moreover, the similar cytotoxicity observed towards A2780 and A2780cis cells (cisplatin-sensitive and cisplatin-resistant, respectively) suggests that our palladium derivatives presumably act with a mechanism of action different than that of the clinically approved platinum drugs. For comparison, we also synthesized Pd-ƞ3-allyl derivatives, which generally showed a slightly higher activity towards ovarian cancer cells and lower activity towards breast cancer cells with respect to their Pd-indenyl congeners.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Sciences and Nanosystems, Università Ca' Foscari, Campus Scientifico, Via Torino 155, 30174 Venezia, Italy.
- Elettra-Sincrotrone Trieste, Area Science Park, S.S. 14 Km 163.5 Basovizza, 34149 Trieste, Italy.
- Pathology Unit, Department of Molecular Biology and Translational Research, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Via Franco Gallini 2, 33081 Avia…
- Dipartimento di Scienze Chimiche, Università Degli Studi di Padova, Via Marzolo 1, 35131 Padova, Italy.
ORCID-Profile: Matteo Mauceri, Flavio Rizzolio, Thomas Scattolin
Förderung
- Italian Association for Cancer Research
- Fondazione AIRC per la Ricerca sul Cancro
Zitieren
APA
Bortolamiol, E., Botter, E., Cavarzerani, E., Mauceri, M., Demitri, N., Rizzolio, F., Visentin, F., & Scattolin, T. (2024). Rational Design of Palladium(II) Indenyl and Allyl Complexes Bearing Phosphine and Isocyanide Ancillary Ligands with Promising Antitumor Activity. Molecules. https://doi.org/10.3390/molecules29020345
Vancouver
Bortolamiol E, Botter E, Cavarzerani E, Mauceri M, Demitri N, Rizzolio F, et al. Rational Design of Palladium(II) Indenyl and Allyl Complexes Bearing Phosphine and Isocyanide Ancillary Ligands with Promising Antitumor Activity. Molecules. 2024. doi:10.3390/molecules29020345
BibTeX
@article{Bortolamiol2024,
author = {Bortolamiol, Enrica and Botter, Eleonora and Cavarzerani, Enrico and Mauceri, Matteo and Demitri, Nicola and Rizzolio, Flavio and Visentin, Fabiano and Scattolin, Thomas},
title = {Rational Design of Palladium(II) Indenyl and Allyl Complexes Bearing Phosphine and Isocyanide Ancillary Ligands with Promising Antitumor Activity},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29020345}
}
EUVIMED